FORM: **49 – ESTROGEN PLUS PROGESTIN SURVEY**

Version: 1 – March 14, 2003

Description: Self-administered; 8-page booklet; data entered at Clinical Center (CC).

When Used: This is a one-time form to be mailed by CCs to E+P Hormone Program participants who were still taking study pills (active or placebo) as of July 8, 2002 (based on an intervention status of "active" from *Form 7 – Participation Status*).

Purpose: To gather data about symptoms and feelings, how participants have managed them, and the use of medications since the participant was asked to stop her E-plus-P study pills in July, 2002.

GENERAL INSTRUCTIONS

1. The form is printed in both English (*Form 49*) and Spanish (*Form 49S*). They are both in a key-enter format.

   For both forms, follow the instructions on the front of the form for marking the answers.

2. Place the participant's barcode label on the front page of the questionnaire and mail to participant. It is advised that CCs request immediate return of the survey and include a self-addressed, stamped return envelope in the mailing.

   A model cover letter was developed by the Behavioral Advisory Committee (BAC) to use as a cover letter for mailing the Form 49 to participants. The model cover letter is optional; however, CCs are encouraged to use the prepared model letter to explain the importance of the survey, acknowledge the participant's time and effort in completing the survey, and address the personal nature of some of the questions (e.g., sexual functioning questions). Any modifications to the cover letter must be sent to the CCC for participant material review. See *Vol. 2, Appendix E.3.6 – Model Cover Letter to Include in Form 49 – Estrogen Plus Progestin Survey Mailing* and an electronic version available in Public Folders.

3. Three weeks after the first mailing, follow-up with non-responders with another mailing.

4. Three weeks after the second mailing, follow-up with non-responders with a telephone call.

5. Do not review the completed form with the participant, but look for skipped pages. Ask the participant to complete pages she may have skipped.

6. Forward the form to Data Entry.

7. Data Entry: Review the form for completeness. Return to the interviewer if one or more pages are not completed. Key-enter the form after the April 15, 2003 WHILMA upgrade. Initial the first page of the form after data entry.

8. File in the participant's file.

Item Instructions

	Date received	Date the CC receives the completed form.
	Reviewed by	Standard 3-digit WHI employee ID.
	Contact type	Mark appropriate box. (See common data items.)
	Visit type	The contact at which the CC receives the completed form. If you receive the form between routine visits, use the non-routine visit type. It is not necessary to record or enter in WHILMA a visit "year" when using the non-routine visit type. Mark appropriate box for visit type and number. (See common data items.)
	Form administration	Method used to administer form to participant: 1 - Self: Participant completed form by herself. 2 - Group: Participant completed the form with a group of other participants. 3 - Interview: CC staff person completed entire form as interview. 4 - Assistance: Participant needed partial assistance from CC staff or others to complete the form.
1.	Date stopped study pills	The date the participant reports she stopped her study pills. Do not fill in a date if the participant leaves this date blank.
2.	Hormone use since stopped study pills	No/yes
2.1	Reasons for hormone use, since stopped study pills.	All the reasons a participant reported for taking hormones since stopping study pills.
3.	Current hormone use	All current hormone preparations the participant reports taking.
4.1-4.42.	Symptoms, since stopping study pills	Participant's view of severity of listed symptoms based on how much they interfere with her usual activities. Level of discomfort associated with each symptom listed.
5.1-5.26.	Dealing with symptoms, since stopping study pills	Participant's view of how effective the behavior was in relieving the symptom. Level of effectiveness for each option listed.
6.1-8.1.	Depression scale	Questions 6.1-8.1 form a depression scale.
9-16.	Anxiety scale	Questions 9-16 form an anxiety scale.
17.	Sexual activity while taking study pills	No/Yes/Don't want to answer.
18.	Sexual activity since stopping study pills	No/Yes/Don't want to answer.
18.1.	Reason not sexually active	All the reasons participant reports for not being sexually active, including don't want to answer.

19-19.6.	Changes in sexual activity since stopping study pills.	Participant's view of whether changes are greater, the same/NA, or less than before stopping study pills (including don't want to answer).
20.	Intercourse since stopping study pills	No/Yes/Don't want to answer.
20.1-20.2.	Changes in intercourse since stopping study pills	Participant's view of changes.
21-21.1	Biphosphonates, currently	No/ Don't know/yes and all preparations participant is currently taking.
22-22.1.	Non-estrogen hormone replacement, currently	No/ Don't know/yes and all preparations participant is currently taking.
23-23.1	Natural hormones, currently	No/ Don't know/yes and all preparations participant is currently taking.
24.	Rate quality of life	Scale representing participant's rating of her quality of life on a continuum, 0 to 10.
25.	Rate sense of well-being	Scale representing participant's rating of her sense of well-being on a continuum, 0 to 10.
26.	Sense of well-being comparison	Scale representing participant's sense of well-being on a continuum, 0 to 4.
27.	Future research	Scale representing participant's interest in future research on a continuum, 0 to 4.